Navigation Links
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Date:1/18/2008

s have occurred in patients also taking other immunosuppressive agents that in addition to their underlying disease could predispose them to infections.

Infections have also been reported in patients receiving HUMIRA alone. Treatment with HUMIRA should not be initiated in patients with active infections. TNF-blocking agents, including HUMIRA, have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Patients at risk for HBV infections should be evaluated for prior evidence of HBV infections before initiating HUMIRA. The combination of HUMIRA and anakinra is not recommended and patients using HUMIRA should not receive live vaccines.

More cases of malignancies have been observed among patients receiving TNF blockers, including HUMIRA, compared to control patients in clinical trials. These malignancies, other than lymphoma and non-melanoma skin cancer, were similar in type and number to what would be expected in the general population. There was an approximately 3.0 fold higher rate of lymphoma in combined controlled and uncontrolled open-label portions of HUMIRA clinical trials. The potential role of TNF-blocking therapy in the development of malignancies is not known. TNF-blocking agents, including HUMIRA, have been associated in rare cases with demyelinating disease and severe allergic reactions. Infrequent reports of serious blood disorders have been reported with TNF-blocking agents.

Worsening congestive heart failure (CHF) has been observed with TNF-blocking agents, including HUMIRA, and new onset CHF has been reported with TNF-blocking agents. Treatment with HUMIRA may result in the formation of autoantibodies and rarely, in development of a lupus-like syndrome.

The most frequent adverse events seen in the placebo-controlled clinical trials in adults with rheumatoid arthritis (HUMIRA vs. placebo) were injection site reactions (20 percent vs. 14 percent),
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Dec. 3, 2010 Streamline Health Solutions, Inc. (Nasdaq: ... quarter fiscal year 2010 financial results for the period ended ... market closes. The Company will conduct a conference call and ... 2010 at 4:30 p.m. ET. Interested parties can ...
... 3, 2010 InfraReDx, Inc. , a medical ... announced that James E. Muller, M.D., founder and chief ... Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference, to be ... San Francisco. The InfraReDx presentation is ...
Cached Medicine Technology:Streamline Health to Announce Third Quarter Fiscal Year 2010 Financial Results on Wednesday, December 8 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... sick children with complex chronic illnesses can receive effective, less ... home," with easy access to a team of dedicated health ... likely to become seriously ill and need either hospitalization or ... at an enhanced medical home clinic at the University of ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Offices of Howard G. Smith,announces a December 3, 2007, ... securities class action lawsuit filed on behalf of shareholders ... or,the "Company")(Nasdaq: MEND ) between February 12, 2007 ... lawsuit is pending in,the United States District Court for ...
... FRANCISCO, Calif., Nov. 8 Monogram,Biosciences, Inc. (Nasdaq: ... CEO, is scheduled to present a corporate overview at ... 2007,at 8:00 a.m. (Eastern Time) at the New York ... or the subsequent archived,recording, log on to http://www.monogrambio.com ...
... risk factor for injury, study finds , THURSDAY, Nov. ... to their medications may cut their risk for fracture, ... a fracture, there,s an increased risk of additional fractures, ... of fractures in osteoporosis patients are hip, spine, and ...
... an overwhelming majority, 90 percent of Americans, claim a ... more religiously diverse than ever before, which is why ... where clients beliefs stem from, says Dr. E. Thomas ... are much less religious than the general population, says ...
... molecular switch in the protein making machinery of cells is ... breast cancer worldwide. The discovery by researchers at NYU School ... called locally advanced breast cancer (LABC)., ... 50 percent or more of breast cancers among women in ...
... Transfer Challenge Awards all have a strong track record in ... , This competition is also about coming up with new ... that research is transformed into products and services that everyone ... record in Knowledge Transfer: , Aston University ...
Cached Medicine News:Health News:Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference 2Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:A molecular switch is linked to a common breast cancer 2Health News:Final of EPSRC's 2007 Knowledge Transfer Challenge Awards 2
... Anatomically Correct Design Is Unique Among All Lid ... Support The Lids Through An Anatomically Correct Arc ... With All Other Lid Speculums Which Pull Straight ... Tarsal Plate As They Open. Gentle Support ...
... Footplates Are Turned 90 Degrees To ... Blade While Incising Tissue. ,Special Mirror-Polished Double ... Penetration.,Pre-Set Blade Extension Settings Of 0.5mm, ... Full Extension.,1mm Wide Snub Nose Diamond ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: